Drug Trial Radar · NCT07832500
A Lot-to-Lot Consistency Clinical Trial of PCV13
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,125
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Sinovac Life Sciences Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 2 years, up to 5 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A Phase IIIb clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13)developed by Sinovac Life Science Co., Ltd will be conducted in children aged 2 to 5 years. The objective of the study is to evaluate the the Lot-to-Lot consistency, immunogenicity and safety of Sinovac PCV13. The trial is a randomized, double-blind phase IIIb clinical trial.
Conditions
- Pneumococcal Infectious Diseases
Interventions
Sinovac PCV13 lot 1Biological
One dose of Sinovac PCV13 lot 1 (0.5ml) was administered
Sinovac PCV13 lot 2Biological
One dose of Sinovac PCV13 lot 2 (0.5ml) was administered
Sinovac PCV13 lot 3Biological
One dose of Sinovac PCV13 lot 3(0.5ml) was administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pneumococcal serotype-specific IgG antibody geometric mean concentration (GMC) 30 days after vaccinationTime frame: 30 days after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention (Xinjiang Uygur Autonomous Region Academy of Preventive Medicine, Xinjiang Uygur Autonomous Region Public Health Inspection and Testing Center)
Ürümqi, Xinjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.